Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TTX-MC138-NODAGA-Cu64
- Development stage
- Phase 1
- Lead developer
- TransCode Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
TTX-MC138-NODAGA-Cu64 is a radioconjugate drug candidate designed for imaging and potential treatment of metastatic solid tumors. It consists of the microRNA-10b (miR-10b) inhibitor TTX-MC138, which is an anti-miR10b antagomir conjugated to ultrasmall iron oxide nanoparticles, chelated with the chelator NODAGA (1,4,7-triazacyclononane,1-glutaric acid-4,7 acetic acid), and radiolabeled with copper Cu 64. The drug is intended to inhibit miR-10b—a microRNA implicated in cancer metastasis—by delivering the antisense oligonucleotide directly to tumor cells. Its mechanism involves both targeted delivery via nanoparticle technology and molecular inhibition of miR-10b function. The compound has been evaluated in a phase 0/early phase 1 clinical trial for advanced metastatic solid tumors using PET-MRI imaging to assess pharmacokinetics and biodistribution[1][2][4][5][7]. Developed by TransCode Therapeutics, it represents a first-in-class approach targeting metastasis through nucleic-acid based therapeutics.
- Other names
- copper Cu 64 NODAGA-TTX-MC138
02
Targets
miR-10b (MicroRNA 10b)
Beyond the preview
Go deeper on TTX-MC138-NODAGA-Cu64.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TTX-MC138-NODAGA-Cu64.